68Ga-DOTA-TATE PET/CT在神经母细胞瘤骨髓受累中的评估
68Ga-DOTA-TATE in Neuroblastoma With Marrow Involvement.
PubMed 文献 · Clin Nucl Med · 2019-01-01
一例22月龄神经母细胞瘤患儿,骨显像和碘代苄胍显像未检出骨骼转移,但平片和MRI提示可疑转移灶;随后行68Ga-DOTA-TATE PET/CT,显示多发骨和骨髓区域摄取,符合转移;右侧髂骨活检病理与神经母细胞瘤浸润一致。
要点
- 骨显像和碘代苄胍显像阴性时,68Ga-DOTA-TATE PET/CT可检出骨和骨髓转移。
- 68Ga-DOTA-TATE PET/CT所示多发骨和骨髓摄取与活检证实的神经母细胞瘤浸润一致。
- 对于常规显像与平片/MRI结果不一致的神经母细胞瘤患儿,可考虑68Ga-DOTA-TATE PET/CT评估。
核心结论
- 在该22月龄神经母细胞瘤患儿中,68Ga-DOTA-TATE PET/CT检出多发骨和骨髓转移,并经右侧髂骨活检病理证实为神经母细胞瘤浸润。
研究设计与样本
- 个案报道:一例22月龄男性神经母细胞瘤患儿,先后行骨显像、碘代苄胍显像、平片、MRI及68Ga-DOTA-TATE PET/CT,并行右侧髂骨活检。
主要发现
- 骨显像和碘代苄胍显像未检出骨骼系统转移。
- 平片和MRI提示可疑转移病灶。
- 68Ga-DOTA-TATE PET/CT显示多发骨和骨髓区域摄取,符合转移。
- 右侧髂骨活检病理检查与神经母细胞瘤浸润一致。
临床怎么用
- 在神经母细胞瘤患儿中,当骨显像和碘代苄胍显像阴性但平片或MRI提示可疑骨/骨髓转移时,可考虑行68Ga-DOTA-TATE PET/CT进一步评估。
局限性
- 本文为单例个案报道,结果不能外推为普遍诊断效能结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A 22-month-old boy diagnosed with neuroblastoma was evaluated by bone scintigraphy and I-metaiodobenzylguanidine scintigraphy, and no metastases to skeletal system was detected. However, plain radiograph and MRI revealed suspected metastatic lesions. The patient was therefore evaluated by Ga-DOTA-TATE PET/CT, and Ga-DOTA-TATE uptake was observed in multiple bone and bone marrow areas, which were consistent with metastases. Biopsy was taken from the right iliac bone, and the pathological examination of the biopsy specimen was coherent with neuroblastoma invasion.
来源:Clin Nucl Med,查看原文。版权归原作者所有。
引用
- Torun N. 68Ga-DOTA-TATE in Neuroblastoma With Marrow Involvement. Clin Nucl Med. 2019. PMID: 30889003. doi:10.1097/RLU.0000000000002539
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。